Difei Yang
Stock Analyst at Mizuho
(2.15)
# 2,950
Out of 5,090 analysts
33
Total ratings
31.03%
Success rate
11.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.54 | +29.87% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $12.11 | +1,551.53% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $0.96 | +3,857.92% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $725 | $8.42 | +8,510.45% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $21.33 | +143.79% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $22.26 | +618.78% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $6.51 | +115.05% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $56.90 | +822.67% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.14 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $13.16 | +112.77% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.31 | +2,037.40% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.54
Upside: +29.87%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $12.11
Upside: +1,551.53%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $0.96
Upside: +3,857.92%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $8.42
Upside: +8,510.45%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $21.33
Upside: +143.79%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $22.26
Upside: +618.78%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $6.51
Upside: +115.05%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $56.90
Upside: +822.67%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.14
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $13.16
Upside: +112.77%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.31
Upside: +2,037.40%